Ignite Creation Date:
2025-12-25 @ 1:20 AM
Ignite Modification Date:
2026-01-02 @ 1:47 AM
Study NCT ID:
NCT00472693
Status:
COMPLETED
Last Update Posted:
2020-04-09
First Post:
2007-05-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer
Sponsor:
Abramson Cancer Center at Penn Medicine
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2007-05
Start Date Type:
None
Primary Completion Date:
2011-04
Primary Completion Date Type:
ACTUAL
Completion Date:
2011-04
Completion Date Type:
ACTUAL
First Submit Date:
2007-05-11
First Submit QC Date:
None
Study First Post Date:
2007-05-14
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2020-04-09
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2020-04-06
Last Update Post Date:
2020-04-09
Last Update Post Date Type:
ACTUAL